5. CONCLUSION
In this systematic review and
network meta-analysis of studies of patients with
macular edema and at least 12 weeks
of follow-up, our findings underscore the notion that any TA by
different routes of injection therapy compared with placebo did increase
IOP risk. RITA is potentially the safest route of injection in macular
edema treatment for the risk of IOP. At 4 and 12 weeks of follow-up, the
highest risk of IOP was found in IVTA, and at 24 weeks of follow-up, the
highest risk became SCTA. This conclusion may help doctors evaluate the
balance of pros and cons of various routes of injection and adjust their
treatment accordingly. In the future, large-scale trials must be
performed to validate the risk identified in the current meta-analysis.